Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al v. Amgen Inc.
Case Number:
1:06-cv-10972
Court:
Nature of Suit:
Judge:
Firms
- Baker & Hostetler
- Buchanan Ingersoll
- Covington & Burling
- Delaney Kester
- Delaney & Kester
- Douglas Whitney Law Offices
- Faegre Drinker
- Fitch Law Partners
- Hogan Lovells
- Kellogg Hansen
- Lesser Newman
- Lipsitz Green
- Morgan Lewis
- Patterson Belknap
- Ropes & Gray
- Whistleblower Law Collaborative
- White & Case
- Williams & Connolly
Companies
Government Agencies
Sectors & Industries:
-
October 24, 2011
Amgen To Pay $780M To Settle Drug Sales Suits
Amgen Inc. said Monday it would pay $780 million to settle allegations over its sales and marketing practices stemming from civil and criminal investigations — including Medicaid claims and a whistleblower suit accusing the drugmaker of bribing health care providers to buy its drug Aranesp.
-
August 26, 2011
Amgen Can't Dodge Kickback Claims In Aranesp Suit
Amgen Inc. on Friday lost a bid for summary judgment in a Massachusetts whistleblower suit alleging the company and others bribed health care providers to purchase Aranesp, but ruled that the company had appropriately calculated the average sale price of the anemia drug.
-
April 04, 2011
Amgen Expert Report Allowed In Aranesp Kickback Suit
A Massachusetts federal judge refused Monday to toss the report of Amgen Inc.'s expert witness in a whistleblower suit accusing Amgen and others of providing kickbacks to health care providers and causing false Medicare claims to increase sales of anemia drug Aranesp.